Literature DB >> 12702540

Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117).

G Fiorentini, S Rossi, G Lanzanova, P Bernardeschi, P Dentico, U De Giorgi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12702540     DOI： 10.1093/annonc/mdg192

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma.

Authors:  Nicolas Penel; Corinne Delcambre; Xavier Durando; Stéphanie Clisant; Mohamed Hebbar; Sylvie Negrier; Charles Fournier; Nicolas Isambert; Frédéric Mascarelli; Frédéric Mouriaux
Journal:  Invest New Drugs       Date:  2008-06-13       Impact factor: 3.850

3.  Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.

Authors:  Armelle Calipel; Solange Landreville; Arnaud De La Fouchardière; Frédéric Mascarelli; Michel Rivoire; Nicolas Penel; Frédéric Mouriaux
Journal:  Clin Exp Metastasis       Date:  2014-03-21       Impact factor: 5.150

4.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.

Authors:  Carlos A Torres-Cabala; Wei-Lien Wang; Jonathan Trent; Dan Yang; Su Chen; John Galbincea; Kevin B Kim; Scott Woodman; Michael Davies; Jose A Plaza; J W Nash; Victor G Prieto; Alexander J Lazar; Doina Ivan
Journal:  Mod Pathol       Date:  2009-08-28       Impact factor: 7.842
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.